CD8A and B-cell non-Hodgkin lymphoma: Preclinical studies in xenogeneic animal models of B-cell lymphoma have shown that CART19 cells manufactured from CD4 and CD8 TN and TCM cells have improved antitumor effect compared with those CART derived from more differentiated T-cell subsets (20, 72).